Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the ...

ZORYVE foam 0.3% shows significant efficacy for scalp and body psoriasis, with FDA review anticipated by May 2025. Arcutis Biotherapeutics, Inc. announced positive results from a pivotal Phase 3 ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the first ...

At Week 8, 70.9% of those treated with ZORYVE foam versus 31.3% treated with vehicle achieved at least 75% improvement in Psoriasis Scalp Severity Index (PSSI-75) (P<.001), another secondary endpoint.

Q1 2025 Management View CEO Frank Watanabe highlighted four key points for the quarter: strong commercial and R&D execution, confidence in sustained growth for 2025 and beyond, growing momentum in the ...

Psoriasis flares here can be more embarrassing ... There are also steroid-free options such as roflumilast (Zoryve) and tapinarof (Vtama) and topical calcineurin inhibitors (pimecrolimus and ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the ...